Epcoritamab Disease Interactions

Epcoritamab can cause serious and fatal infections. Patients should be evaluated for signs/symptoms of infection prior to epcoritamab treatment; administration should be avoided in patients with active infection. Pneumocystis jirovecii pneumonia prophylaxis should be provided before starting epcoritamab. Initiation of prophylaxis against herpes virus should be considered prior to starting treatment to prevent herpes zoster reactivation.

Epcoritamab can cause adverse reactions that impair cognition or consciousness. Patients at increased risk should be advised to refrain from operating heavy/potentially dangerous machinery until resolution.

The effects of moderate to severe liver dysfunction (total bilirubin greater than 1.5 times the upper limit of normal [1.5 x ULN] and any AST) on the pharmacokinetics of epcoritamab are unknown. Compared to normal liver function, no clinically significant differences in epcoritamab pharmacokinetics were observed based on mild liver dysfunction ((total bilirubin up to 1 x ULN and AST greater than ULN, or total bilirubin 1 to 1.5 x ULN and any AST), after accounting for differences in body weight.

The effects of severe renal dysfunction (CrCl 15 to less than 30 mL/min) or end-stage renal disease (CrCl less than 15 mL/min) on the pharmacokinetics of epcoritamab are unknown. Compared to normal renal function, no clinically significant differences in epcoritamab pharmacokinetics were observed based on mild to moderate renal dysfunction (CrCl 30 to less than 90 mL/min [as estimated by Cockcroft-Gault formula]), after accounting for differences in body weight.